Inui S. Nalfurafine hydrochloride to treat pruritus: a review. Clin Cosmet Investig Dermatol. 2015;8:249–55.

Article  PubMed  PubMed Central  Google Scholar 

Moman RN, Mowery ML, Kelley B. Alfentanil. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470456/.

Prommer E. Levorphanol: the forgotten opioid. Support Care Cancer. 2007;15:259–64.

Article  PubMed  Google Scholar 

Singh D, Saadabadi A. Naltrexone. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK534811/.

Brenner DM, Sayuk GS. Current US Food and Drug Administration-approved pharmacologic therapies for the treatment of irritable bowel syndrome with diarrhea. Adv Ther. 2020;37:83–96.

Article  PubMed  Google Scholar 

Corsetti M, Whorwell P. New therapeutic options for IBS: the role of the first in class mixed µ- opioid receptor agonist and δ-opioid receptor antagonist (mudelta) eluxadoline. Expert Rev Gastroenterol Hepatol. 2017;11:285–92.

Article  CAS  PubMed  Google Scholar 

Rorick-Kehn LM, Witkin JM, Statnick MA, Eberle EL, McKinzie JH, Kahl SD, et al. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. Neuropharmacology. 2014;77:131–44.

Article  CAS  PubMed  Google Scholar 

Zhou Y, Kreek MJ. Combination of clinically utilized kappa-opioid receptor agonist nalfurafine with low-dose naltrexone reduces excessive alcohol drinking in male and female mice. Alcohol Clin Exp Res. 2019;43:1077–90.

CAS  PubMed  PubMed Central  Google Scholar 

Knoll AT, Carlezon WA. Dynorphin, stress, and depression. Brain Res. 2010;1314:56–73.

Article  CAS  PubMed  Google Scholar 

Carlezon WA, Béguin C, Knoll AT, Cohen BM. Kappa-opioid ligands in the study and treatment of mood disorders. Pharm Ther. 2009;123:334–43.

Article  CAS  Google Scholar 

Domi E, Barbier E, Augier E, Augier G, Gehlert D, Barchiesi R, et al. Preclinical evaluation of the kappa-opioid receptor antagonist CERC-501 as a candidate therapeutic for alcohol use disorders. Neuropsychopharmacology. 2018;43:1805–12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carlezon WA, Krystal AD. Kappa-opioid antagonists for psychiatric disorders: from bench to clinical trials. Depress Anxiety. 2016;33:895–906.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wee S, Orio L, Ghirmai S, Cashman JR, Koob GF. Inhibition of kappa opioid receptors attenuated increased cocaine intake in rats with extended access to cocaine. Psychopharmacology. 2009;205:565–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Walker BM, Zorrilla EP, Koob GF. Systemic κ-opioid receptor antagonism by nor-binaltorphimine reduces dependence-induced excessive alcohol self-administration in rats. Addiction Biol. 2011;16:116–9.

Article  CAS  Google Scholar 

Walker BM, Koob GF. Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence. Neuropsychopharmacology. 2008;33:643–52.

Article  CAS  PubMed  Google Scholar 

Valenza M, Windisch KA, Butelman ER, Reed B, Kreek MJ. Effects of Kappa opioid receptor blockade by LY2444296 HCl, a selective short-acting antagonist, during chronic extended access cocaine self-administration and re-exposure in rat. Psychopharmacology. 2020;237:1147–60.

Article  CAS  PubMed  Google Scholar 

Uhari-Väänänen J, Eteläinen T, Bäckström P, Oinio V, Carroll FI, Raasmaja A, et al. The selective κ-opioid receptor antagonist JDTic attenuates the alcohol deprivation effect in rats. Eur Neuropsychopharmacol. 2019;29:1–11. https://doi.org/10.1016/j.euroneuro.2019.10.003.

Mague SD, Pliakas AM, Todtenkopf MS, Tomasiewicz HC, Zhang Y, Stevens WC Jr, et al. Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. J Pharm Exp Ther. 2003;305:323–30.

Article  CAS  Google Scholar 

Pliakas AM, Carlson RR, Neve RL, Konradi C, Nestler EJ, Carlezon WA Jr. Altered responsiveness to cocaine and increased immobility in the forced swim test associated with elevated cAMP response element-binding protein expression in nucleus accumbens. J Neurosci. 2001;21:7397–403.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Knoll AT, Meloni EG, Thomas JB, Carroll FI, Carlezon WA. Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats. J Pharm Exp Ther. 2007;323:838–45.

Article  CAS  Google Scholar 

Land BB, Bruchas MR, Lemos JC, Xu M, Melief EJ, Chavkin C. The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. J Neurosci. 2008;28:407–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bruchas MR, Land BB, Chavkin C. The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. Brain Res. 2010;1314:44–55.

Article  CAS  PubMed  Google Scholar 

Jacobson ML, Wulf HA, Browne CA, Lucki I. The kappa opioid receptor antagonist aticaprant reverses behavioral effects from unpredictable chronic mild stress in male mice. Psychopharmacology. 2020;237:3715–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carlezon WA Jr, Béguin C, DiNieri JA, Baumann MH, Richards MR, Todtenkopf MS, et al. Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharm Exp Ther. 2006;316:440–7.

Article  CAS  Google Scholar 

Wee S, Koob GF. The role of the dynorphin-κ opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology. 2010;210:121–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. 2016;3:760–73.

Article  PubMed  PubMed Central  Google Scholar 

Jackson KJ, Jackson A, Carroll FI, Damaj MI. Effects of orally-bioavailable short-acting kappa opioid receptor-selective antagonist LY2456302 on nicotine withdrawal in mice. Neuropharmacology. 2015;97:270–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Daunais JB, Roberts DCS, McGinty JF. Cocaine self-administration increases preprodynorphin, but not c-fos, mRNA in rat striatum. Neuroreport. 1993;4:543–6.

Article  CAS  PubMed  Google Scholar 

Hurd YL, Herkenham M. Molecular alterations in the neostriatum of human cocaine addicts. Synapse. 1993;13:357–69.

Article  CAS  PubMed  Google Scholar 

Mathieu-Kia AM, Besson MJ. Repeated administration of cocaine, nicotine and ethanol: effects on preprodynorphin, preprotachykinin A and preproenkephalin mRNA expression in the dorsal and the ventral striatum of the rat. Mol Brain Res. 1998;54:141–51.

Article  CAS  PubMed  Google Scholar 

Brandon CL, Steiner H. Repeated methylphenidate treatment in adolescent rats alters gene regulation in the striatum. Eur J Neurosci. 2003;18:1584–92.

Article  PubMed  Google Scholar 

di Benedetto M, D’Addario C, Candeletti S, Romualdi P. Chronic and acute effects of 3,4-methylenedioxy-N-methylamphetamine (‘Ecstasy’) administration on the dynorphinergic system in the rat brain. Neuroscience. 2006;137:187–96.

Article  PubMed  Google Scholar 

Przewłocka B, Turchan J, Lasoń W, Przewłocki R. Ethanol withdrawal enhances the prodynorphin system activity in the rat nucleus accumbens. Neurosci Lett. 1997;238:13–6.

Article  PubMed  Google Scholar 

Turchan J, Przewłocka B, Lasoń W, Przewłocki R. Effects of repeated psychostimulant administration on the prodynorphin system activity and kappa opioid receptor density in the rat brain. Neuroscience. 1998;85:1051–9.

Article  CAS  PubMed  Google Scholar 

Marinelli PW, Lam M, Bai L, Quirion R, Gianoulakis C. A microdialysis profile of dynorphin A1-8 release in the rat nucleus accumbens following alcohol administration. Alcohol Clin Exp Res. 2006;30:982–90.

Article  CAS  PubMed  Google Scholar 

Unterwald EM, Rubenfeld JM, Kreek MJ. Repeated cocaine administration upregulates κ and μ but not δ opioid receptors. Neuroreport. 1994;5:1613–6.

Article  CAS  PubMed  Google Scholar 

Karpyak VM, Winham SJ, Preuss UW, Zill P, Cunningham JM, Walker DL, et al. Association of the PDYN gene with alcohol dependence and the propensity to drink in negative emotional states. Int J Neuropsychopharmacol. 2013;16:975–85.

Article  CAS  PubMed  Google Scholar 

Bazov I, Sarkisyan D, Kononenko O, Watanabe H, Yakovleva T, Hansson AC, et al. Dynorphin and κ-opioid receptor dysregulation in the dopaminergic reward system of human alcoholics. Mol Neurobiol. 2018;55:7049–61.

Article  CAS  PubMed  PubMed Central  Google Scholar